Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab versus Bevacizumab plus FOLFOX as first-line therapy in RAS wild-type metastatic colorectal cancer
2014-000543-33Phase 2Completed
- Sponsor
- Antwerp University Hospital
- Start
- Jun 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab, bevacizumab, fluorouracil and oxaliplatin in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Antwerp University Hospital. Primary endpoint: Progression-free survival rate at 1 year. Started Jun 2014; status: completed.
02
Drugs
panitumumabbevacizumabfluorouraciloxaliplatin
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2014-000543-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000543-33.